NeuroSense Therapeutics Ltd. (NASDAQ:NRSN – Free Report) – Stock analysts at HC Wainwright issued their FY2026 earnings per share estimates for shares of NeuroSense Therapeutics in a report released on Thursday, September 3rd. HC Wainwright analyst L. Egana-Gorrono anticipates that the company will earn ($0.37) per share for the year. HC Wainwright has a “Buy” rating on the stock. The consensus estimate for NeuroSense Therapeutics’ current full-year earnings is ($0.38) per share. HC Wainwright also issued estimates for NeuroSense Therapeutics’ FY2027 earnings at ($0.53) EPS, FY2028 earnings at ($0.68) EPS, FY2029 earnings at ($0.75) EPS and FY2030 earnings at $0.93 EPS.
Separately, Weiss Ratings lowered shares of NeuroSense Therapeutics from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Thursday, July 30th. One analyst has rated the stock with a Strong Buy rating, three have given a Buy rating, one has assigned a Hold rating and one has assigned a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $8.50.
NeuroSense Therapeutics Price Performance
Shares of NeuroSense Therapeutics stock opened at $0.42 on Monday. The firm has a market cap of $15.79 million, a price-to-earnings ratio of -0.77 and a beta of 1.60. The stock has a 50-day simple moving average of $0.54 and a 200-day simple moving average of $0.70. NeuroSense Therapeutics has a 52-week low of $0.25 and a 52-week high of $1.98.
Insider Buying and Selling at NeuroSense Therapeutics
In related news, CFO Or Eisenberg acquired 250,000 shares of the company’s stock in a transaction on Tuesday, June 16th. The stock was purchased at an average cost of $0.80 per share, for a total transaction of $200,000.00. Following the completion of the purchase, the chief financial officer directly owned 1,504,050 shares of the company’s stock, valued at $1,203,240. The trade was a 19.94% increase in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Alon Ben-Noon acquired 250,000 shares of the business’s stock in a transaction on Tuesday, June 16th. The shares were bought at an average cost of $0.80 per share, with a total value of $200,000.00. Following the completion of the acquisition, the chief executive officer owned 4,534,233 shares of the company’s stock, valued at approximately $3,627,386.40. This trade represents a 5.84% increase in their position. The SEC filing for this purchase provides additional information. 27.40% of the stock is owned by insiders.
Institutional Investors Weigh In On NeuroSense Therapeutics
Large investors have recently made changes to their positions in the company. Two Sigma Investments LP acquired a new stake in shares of NeuroSense Therapeutics during the 3rd quarter worth about $26,000. Jane Street Group LLC bought a new stake in NeuroSense Therapeutics during the second quarter worth about $54,000. Yorkville Advisors Global LP bought a new stake in NeuroSense Therapeutics during the second quarter worth about $56,160. Finally, Squarepoint Ops LLC increased its holdings in shares of NeuroSense Therapeutics by 91.0% during the third quarter. Squarepoint Ops LLC now owns 95,375 shares of the company’s stock worth $119,000 after buying an additional 45,450 shares in the last quarter. Institutional investors own 1.04% of the company’s stock.
About NeuroSense Therapeutics
NeuroSense Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of novel therapies for neurodegenerative and age-related neurological disorders. The company’s primary mission is to address unmet medical needs in diseases characterized by protein aggregation, chronic inflammation and cellular senescence in the central nervous system.
At the core of NeuroSense’s approach is a proprietary senotherapeutic platform designed to selectively target and clear senescent cells that contribute to neurodegeneration.
Featured Articles
- Five stocks we like better than NeuroSense Therapeutics
- Tesla’s Robotaxi Launch Wasn’t the Moment Investors Expected
- Despite Post-Earnings Drop, Wall Street Analysts Eye New Highs for Broadcom Stock
- Morgan Stanley Eyes Good Things Ahead for Meta After $18 Billion Legal Settlement
- Q3 Earnings Could Be the Catalyst the Market Has Been Waiting For
Receive News & Ratings for NeuroSense Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for NeuroSense Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.
